SILVER SPRING, Md., June 17, 2026
The U.S. Food and Drug Administration (FDA) has approved the first generic version of Xofluza® (baloxavir marboxil) tablets, providing patients with a single-dose oral treatment for acute uncomplicated influenza and post-exposure prophylaxis. Approved ahead of the 2026–2027 influenza season, the generic therapy is indicated for patients aged five years and older and is expected to improve access to affordable antiviral treatment by increasing competition in the marketplace. The approval was granted to Norwich Pharmaceuticals, Inc., marking an important milestone in expanding availability of generic influenza medicines.
First Generic Single-Dose Influenza Therapy Approved
The newly approved generic baloxavir marboxil tablets are indicated for the treatment of acute uncomplicated influenza in patients aged five years and older who have experienced symptoms for 48 hours or less and are either otherwise healthy or at high risk of influenza-related complications. The medicine is also approved for post-exposure prophylaxis, helping prevent influenza following close contact with an infected individual. Baloxavir marboxil remains the first and only approved single-dose oral antiviral treatment in its class, offering a convenient alternative to multi-dose influenza therapies while improving patient adherence during flu season.
Safety Profile and Clinical Considerations
The FDA noted that baloxavir marboxil tablets are contraindicated in patients with known hypersensitivity to the drug or any of its ingredients. The prescribing information also includes warnings regarding the potential for treatment-emergent antiviral resistance, particularly in younger pediatric populations. The most commonly reported adverse events include diarrhea, bronchitis, nausea, sinusitis, and headache. Healthcare providers are advised to follow the complete prescribing information for recommended dosing and safety guidance when treating eligible patients.
Generic Approval Expands Patient Access Before Flu Season
Advertisement
According to the FDA, approximately 90% of prescriptions filled in the United States are for generic medicines, making generic competition an important driver of affordability and healthcare access. The approval of Norwich Pharmaceuticals’ generic baloxavir marboxil tablets is expected to increase treatment availability ahead of the 2026–2027 influenza season while supporting public health efforts to reduce the burden of seasonal influenza. The decision also aligns with the FDA’s broader initiative to encourage generic drug competition and improve patient access to effective therapies.
Source: FDA press release
